N Villamor
Overview
Explore the profile of N Villamor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
88
Citations
1469
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gil-Lianes J, Mozas P, Baumann T, Combalia A, Baliu-Pique C, Garcia A, et al.
Actas Dermosifiliogr
. 2024 Jun;
116(2):169-175.
PMID: 38852841
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematodermic neoplasm usually involving the skin. In this retrospective case series, 10 cases of BPDCN were identified, 90% of...
2.
Rovira M, Villamor N, Cobo F, Fernandez-Aviles F, Lopez-Guerra M, Guijarro F, et al.
Bone Marrow Transplant
. 2020 Mar;
55(9):1860-1861.
PMID: 32203265
No abstract available.
3.
Magnano L, Balague O, Dlouhy I, Rovira J, Karube K, Pinyol M, et al.
Ann Oncol
. 2017 Oct;
28(11):2799-2805.
PMID: 29045517
Background: The co-existence at diagnosis of follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) components (FL/DLBCL) has been considered a transformed lymphoma and accordingly treated although clinicobiological information on...
4.
Nadeu F, Clot G, Delgado J, Martin-Garcia D, Baumann T, Salaverria I, et al.
Leukemia
. 2017 Sep;
32(3):645-653.
PMID: 28924241
Genome studies of chronic lymphocytic leukemia (CLL) have revealed the remarkable subclonal heterogeneity of the tumors, but the clinical implications of this phenomenon are not well known. We assessed the...
5.
Rozman M, Ribera J, Ispizua A, Matutes E, Villamor N, Corrons J, et al.
Leuk Lymphoma
. 2016 Jul;
3(4):301-3.
PMID: 27464251
A 77 year-old male with refractory anemia receiving only supportive therapy presented with an acute transformation six years following diagnosis. The lineage of the blast cells could not be ascertained...
6.
Montesinos P, Cabrero M, Valcarcel D, Rovira M, Garcia-Marco J, Loscertales J, et al.
Bone Marrow Transplant
. 2016 May;
51(10):1404-1407.
PMID: 27214073
No abstract available.
7.
Rawstron A, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, et al.
Leukemia
. 2015 Dec;
30(4):929-36.
PMID: 26639181
In chronic lymphocytic leukemia (CLL) the level of minimal residual disease (MRD) after therapy is an independent predictor of outcome. Given the increasing number of new agents being explored for...
8.
Queiros A, Villamor N, Clot G, Martinez-Trillos A, Kulis M, Navarro A, et al.
Leukemia
. 2014 Aug;
29(3):598-605.
PMID: 25151957
Prospective identification of patients with chronic lymphocytic leukemia (CLL) destined to progress would greatly facilitate their clinical management. Recently, whole-genome DNA methylation analyses identified three clinicobiologic CLL subgroups with an...
9.
Baliakas P, Hadzidimitriou A, Sutton L, Rossi D, Minga E, Villamor N, et al.
Leukemia
. 2014 Jun;
29(2):329-36.
PMID: 24943832
Through the European Research Initiative on chronic lymphocytic leukemia (CLL) (ERIC), we screened 3490 patients with CLL for mutations within the NOTCH1 (n=3334), SF3B1 (n=2322), TP53 (n=2309), MYD88 (n=1080) and...
10.
Lopez-Guerra M, Xargay-Torrent S, Rosich L, Montraveta A, Roldan J, Matas-Cespedes A, et al.
Leukemia
. 2014 May;
29(1):96-106.
PMID: 24781018
Targeting Notch signaling has emerged as a promising therapeutic strategy for chronic lymphocytic leukemia (CLL), especially for the poor prognostic subgroup of NOTCH1-mutated patients. Here, we report that the γ-secretase...